Compare · AVTR vs WAT
AVTR vs WAT
Side-by-side comparison of Avantor Inc. (AVTR) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $28.68B, about 5.4x AVTR ($5.31B).
- Both names hit the wire about 8 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Avantor Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $5.31B
- $28.68B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- 1995
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 25
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest AVTR
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports First Quarter 2026 Results
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
- Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
- Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
- SEC Form 4 filed by Eck Steven W
- Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest WAT
- Amendment: SEC Form SCHEDULE 13G/A filed by Waters Corporation
- Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
- Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
- SEC Form DEFA14A filed by Waters Corporation
- SEC Form DEF 14A filed by Waters Corporation
- Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
- SEC Form 4 filed by Bennett Jianqing
- Waters upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Jiang Wei
- SEC Form 4 filed by Knight Heather